LSP-249 is a plasma kallikrein inhibitor for treatment of angioedema.
Uses
LSP-249 (example 35), extracted from patent WO2016011209A1, is a plasma kallikrein inhibitor under the study for angioedema, with an EC50 less than 100 nM in cell[1].
References
[1] Andrew Mcdonald, et al. Therapeutic inhibitory compounds. Patent. WO2016011209A1.
